Entrada Therapeutics Inc (TRDA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $199.28M
Last updated: Nov 17, 2026 at 4:19 PM ET
Entrada Therapeutics Inc (TRDA) Statistics
Entrada Therapeutics (TRDA) has a market cap of $199.28M and an enterprise value of $134.35M. It kept -4057.98% of revenue as net income over the last 12 months. Revenue fell 93.54% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 32.58% below the market cap, as cash exceeds debt.
| Market Cap | $199.28M |
|---|---|
| Enterprise Value | $134.35M |
| Latest price (Nov 17, 2026) | $4.96 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 52.8x and 1.1x. Its year-end P/S ranged from 2.9x to 16.6x from 2023 to 2025.
| P/S Ratio | 52.8x |
|---|---|
| Forward P/S | 49.2x |
| P/B Ratio | 1.1x |
Price Statistics
The stock is down 43.31% over 52 weeks and trades 9.82% below its 50-day average.
| Beta (1Y) | 1.55 |
|---|---|
| 52-Week Change | -43.31% |
| 1-Month Change | +2.90% |
| 3-Month Change | -36.25% |
| 6-Month Change | -12.21% |
| 5-Year Change | -81.06% |
| Total Return (1Y) | -43.31% |
| Total Return (3Y CAGR) | -32.62% |
| Total Return (5Y CAGR) | -31.90% |
| Return vs SPY (1Y) | -55.32% |
| Max Drawdown (1Y) | -72.74% |
| Max Drawdown (3Y) | -79.76% |
| Sharpe Ratio (1Y) | -0.53 |
| Correlation with SPY (1Y) | 0.19 |
| 50-Day Average | $5.50 |
| 200-Day Average | $8.39 |
| 52-Week Range | $4.11 to $16.45 |
| RSI (14 Days) | 48.2 |
| Average Volume (20 Days) | 510.06K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.85x current liabilities, and total debt is 0.24x shareholder equity.
| Current Ratio | 7.85x |
|---|---|
| Quick Ratio | 7.85x |
| Debt / Equity | 0.24x |
| Interest Coverage | -2.41x |
Returns and Efficiency
Return on invested capital is -69.68% over the last 12 months, against a 5-year average of -51.58%.
| Return on Equity (ROE) | -81.37% |
|---|---|
| Return on Assets (ROA) | -60.47% |
| Return on Invested Capital (ROIC) | -69.68% |
| ROE (5Y Average) | -19.21% |
| ROA (5Y Average) | -16.26% |
| ROIC (5Y Average) | -51.58% |
| Asset Turnover | 0.01x |
Scores
TRDA has an Altman Z-Score of -1.54, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -1.54 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $3.98M over the last 12 months.
| Revenue | $3.98M |
|---|---|
| Revenue Growth (YoY) | -93.54% |
| Gross Profit | $3.98M |
| Operating Income | -$171.16M |
| Pretax Income | -$161.19M |
| Net Income | -$161.39M |
| Reported EPS (TTM) | -$3.84 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 74.31% of the $266.88M in total assets.
| Cash and Equivalents | $112.24M |
|---|---|
| Total Debt | $47.31M |
| Net Cash | $64.92M |
| Net Cash Per Share | $1.53 |
| Working Capital | $177.09M |
| Shareholder Equity | $198.32M |
| Book Value Per Share | $4.68 |
| Total Assets | $266.88M |
| Total Liabilities | $68.56M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $423.00K of capital spending, operating cash flow left -$136.75M of free cash flow.
| Operating Cash Flow | -$136.32M |
|---|---|
| Capital Expenditures | $423.00K |
| Free Cash Flow | -$136.75M |
| FCF Per Share | -$3.51 |
| Depreciation and Amortization | $5.09M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -4303.82%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -4303.82% |
| Pretax Margin | -4053.16% |
| Net Margin | -4057.98% |
| FCF Margin | -3438.47% |
Growth
| Book Value Per Share Growth (2Y CAGR) | +0.94% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +0.94% |
Dividends and Yields
TRDA does not pay a dividend. Its free cash flow yield is -65.06%.
| FCF Yield | -65.06% |
|---|---|
| Buyback Yield | -0.07% |
| Shareholder Yield | -0.07% |
Peer Position
Against 9 similar companies, TRDA has the highest P/S.
P/S RatioPeer median 7.0x
ROICPeer median -8.94%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +0.18%
| P/S Ratio | 52.8x vs 7.0x median |
|---|---|
| ROIC | -69.68% vs -8.94% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -93.54% vs +0.18% median |
Analyst Forecast
Consensus estimates put revenue growth at -10.52% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -10.52% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TRDA
What is TRDA's market cap?
Entrada Therapeutics has a market cap of $199.28M. Its enterprise value, which adds debt and subtracts cash, is $134.35M.
How many shares of TRDA are outstanding?
Entrada Therapeutics has 42.37M shares outstanding. The count is up 2.20% from a year earlier.
Does TRDA pay a dividend?
No. Entrada Therapeutics does not pay a dividend.
How much debt does TRDA have?
Entrada Therapeutics has $47.31M of total debt and $112.24M of cash and equivalents, a net cash position of $64.92M.
TRDA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors